About TG Therapeutics
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: TGTX
- Previous Close: $5.60
- 50 Day Moving Average: $4.83
- 200 Day Moving Average: $5.83
- 52-Week Range: $4.10 - $10.50
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.34
- P/E Growth: 0.00
- Market Cap: $322.91M
- Outstanding Shares: 54,731,000
- Beta: 2.1
- Net Margins: -47,494.08%
- Return on Equity: -83.18%
- Return on Assets: -70.72%
Companies Related to TG Therapeutics:
- Current Ratio: 4.23%
- Quick Ratio: 4.23%
What is TG Therapeutics' stock symbol?
TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."
Where is TG Therapeutics' stock going? Where will TG Therapeutics' stock price be in 2017?
7 brokerages have issued 1 year price targets for TG Therapeutics' shares. Their predictions range from $6.40 to $33.00. On average, they expect TG Therapeutics' stock price to reach $22.68 in the next twelve months.
When will TG Therapeutics announce their earnings?
TG Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.
What are analysts saying about TG Therapeutics stock?
Here are some recent quotes from research analysts about TG Therapeutics stock:
According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (1/25/2017)
FBR & Co analysts commented, "We view the 6.7 months PFS for single agent mirvetuximab soravtansine in platinum resistant ovarian cancer as interesting when compared with 6.8 months for Avastin +chemotherapy in Phase 3. We acknowledge that the Immunogen data are Phase 1 vs. Phase 3 for Avastin and involve a small number of patients." (5/19/2016)
Who owns TG Therapeutics stock?
TG Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (6.93%), State Street Corp (1.24%), Eventide Asset Management LLC (0.98%), Guggenheim Capital LLC (0.49%), Teachers Retirement System of The State of Kentucky (0.29%) and A.R.T. Advisors LLC (0.10%). Company insiders that own TG Therapeutics stock include Sean A Power and William James Kennedy.
Who sold TG Therapeutics stock? Who is selling TG Therapeutics stock?
TG Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC.
Who bought TG Therapeutics stock? Who is buying TG Therapeutics stock?
TG Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Guggenheim Capital LLC, A.R.T. Advisors LLC, State Street Corp, Raymond James Financial Services Advisors Inc., Ellington Management Group LLC and Frontier Wealth Management LLC.
How do I buy TG Therapeutics stock?
Shares of TG Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of TG Therapeutics stock cost?
One share of TG Therapeutics stock can currently be purchased for approximately $5.90.